ABBV - AbbVie Inc.
Close
179.36
-0.310 -0.173%
Share volume: 93,442
Last Updated: Tue 07 Jan 2025 08:29:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.90%
PREVIOUS CLOSE
CHG
CHG%
$179.67
-0.31
-0.17%
View ratios
| Fiscal Date | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2023-05-05 | 2023-08-07 | 2023-11-06 | 2024-02-20 | 2024-05-03 | |
| Total revenue | 12.225 B | 13.865 B | 13.927 B | 14.301 B | 12.310 B | |
| Cost of revenue | 3.986 B | 4.240 B | 6.485 B | 5.704 B | 4.094 B | |
| Gross profit | 8.239 B | 9.625 B | 7.442 B | 8.597 B | 8.216 B | |
| 16.82% | -22.68% | 15.52% | -4.43% | |||
| Operating expenses | 5.331 B | 5.001 B | 5.095 B | 5.120 B | 5.254 B | |
| Selling general and admin | 3.039 B | 3.268 B | 3.372 B | 3.193 B | 3.315 B | |
| Research and development | 2.292 B | 1.733 B | 1.723 B | 1.927 B | 1.939 B | |
| Total expenses | 9.317 B | 9.241 B | 11.580 B | 10.824 B | 9.348 B | |
| -0.82% | 25.31% | -6.53% | -13.64% | |||
| Operating income | 2.908 B | 4.624 B | 2.347 B | 3.477 B | 2.962 B | |
| Ebit | 2.908 B | 4.624 B | 2.347 B | 3.477 B | 2.962 B | |
| Pretax income | 475.000 M | 2.610 B | 1.953 B | 1.212 B | 1.755 B | |
| 449.47% | -25.17% | -37.94% | 44.80% | |||
| Income tax | 234.000 M | 583.000 M | 172.000 M | 388.000 M | 383.000 M | |
| Net income basic | 228.000 M | 2.013 B | 1.767 B | 812.000 M | 1.359 B | |
| 782.89% | -12.22% | -54.05% | 67.36% | |||
| Net income | 228.000 M | 2.013 B | 1.767 B | 812.000 M | 1.359 B | |
| 782.89% | -12.22% | -54.05% | 67.36% |